药械

订阅

MedSci主页 / 所有栏目 / 药械

GW制药领军药Epidiolex三期临床成功，股价立马翻倍！

2016-03-21 佚名 生物谷

EpidiolexGW制药孤儿药
关注

伦敦GW制药公司发布公告称，其以大麻提取物为活性成分的epilepsy治疗罕见病Dravet综合征三期临床表现良好。该三期临床结果将大大提高通过FDA批准上市几率。这则重大利好使其股价暴涨一倍多，从38美元一度飙到91美元，让不少投资者乐开了花。 Epidiolex 是一种口服的、高纯度 CBD 提取物液体制剂，CBD 是一种来自大麻植物的非精神类成分，不会引起幻觉。GW坚信该药能减少一

伦敦GW制药公司发布公告称，其以大麻提取物为活性成分的epilepsy治疗罕见病Dravet综合征三期临床表现良好。该三期临床结果将大大提高通过FDA批准上市几率。这则重大利好使其股价暴涨一倍多，从38美元一度飙到91美元，让不少投资者乐开了花。

Epidiolex 是一种口服的、高纯度 CBD 提取物液体制剂，CBD 是一种来自大麻植物的非精神类成分，不会引起幻觉。GW坚信该药能减少一些严重儿童癫痫的痉挛发作。美国 FDA 曾先后授予该公司用于治疗儿童 Lennox-Gastaut 综合征 (LGS) 的药物Epidiolex 孤儿药资格和Dravet 综合征孤儿药资格。

GW称，在治疗罕见病Dravet综合征的三期临床试验中，120名Dravet综合征患者一半给药Epidiolex一半给安慰剂，14周后，病人平均每月发作减少39%，显着高于安慰剂组的13%。

安全性方面，8位病人在临床试验中因副作用退出试验，而安慰剂组只有1位。但是产生副作用的8患者称，副作用较为温和。

公司现在计划会见FDA以推进Epidiolex上市。GW还在开展治疗LGS综合征的三期临床，同时还在计划第三个癫痫类适应症的三期临床。

GW为美国未来市场下了大功夫。去年公司的CEO Justin Gover专门飞去南加州与艾尔建的Julian Gangolli会面商讨该药在北美业务运作，为Epidiolex美国商业运营奠定基础，以推动Epidiolex尽快上市。

LGS 是一种严重形式的儿童发作性癫痫。癫痫发作类型因患者而异，包括强直性发作、失张力发作、非典型失神发作和肌阵挛发作。大多数 LGS 儿童会经历某些程度的智力功能或信息处理功能的损伤，以及发育迟缓和行为障碍。LGS 可由大脑畸形、围产期窒息、严重头部外伤、中枢神经系统感染和遗传退行性或代谢症状引起。据估计，美国大约有 1.4 万 -1.85 万 LGS 患者，欧洲约有 2.3 万 -3.1 万患者。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991745, encodeId=62471991e45d4, content=<a href='/topic/show?id=4e9a835154' target=_blank style='color:#2F92EE;'>#GW制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8351, encryptionId=4e9a835154, topicName=GW制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffd5416, createdName=bettycmoon, createdTime=Tue Oct 11 04:04:00 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991300, encodeId=437a1991300f6, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu May 05 06:04:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581567, encodeId=d233158156eaa, content=<a href='/topic/show?id=938b68e713' target=_blank style='color:#2F92EE;'>#Epidiolex#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6877, encryptionId=938b68e713, topicName=Epidiolex)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acc16815920, createdName=ms3415360956839622, createdTime=Wed Mar 23 04:04:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72660, encodeId=9cbce26608f, content=好，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 13:00:00 CST 2016, time=2016-03-22, status=1, ipAttribution=)]
    2016-10-11 bettycmoon

    #GW制药#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1991745, encodeId=62471991e45d4, content=<a href='/topic/show?id=4e9a835154' target=_blank style='color:#2F92EE;'>#GW制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8351, encryptionId=4e9a835154, topicName=GW制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffd5416, createdName=bettycmoon, createdTime=Tue Oct 11 04:04:00 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991300, encodeId=437a1991300f6, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu May 05 06:04:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581567, encodeId=d233158156eaa, content=<a href='/topic/show?id=938b68e713' target=_blank style='color:#2F92EE;'>#Epidiolex#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6877, encryptionId=938b68e713, topicName=Epidiolex)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acc16815920, createdName=ms3415360956839622, createdTime=Wed Mar 23 04:04:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72660, encodeId=9cbce26608f, content=好，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 13:00:00 CST 2016, time=2016-03-22, status=1, ipAttribution=)]
    2016-05-05 楚秀娟

    #三期临床#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1991745, encodeId=62471991e45d4, content=<a href='/topic/show?id=4e9a835154' target=_blank style='color:#2F92EE;'>#GW制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8351, encryptionId=4e9a835154, topicName=GW制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffd5416, createdName=bettycmoon, createdTime=Tue Oct 11 04:04:00 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991300, encodeId=437a1991300f6, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu May 05 06:04:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581567, encodeId=d233158156eaa, content=<a href='/topic/show?id=938b68e713' target=_blank style='color:#2F92EE;'>#Epidiolex#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6877, encryptionId=938b68e713, topicName=Epidiolex)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acc16815920, createdName=ms3415360956839622, createdTime=Wed Mar 23 04:04:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72660, encodeId=9cbce26608f, content=好，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 13:00:00 CST 2016, time=2016-03-22, status=1, ipAttribution=)]
    2016-03-23 ms3415360956839622

    #Epidiolex#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1991745, encodeId=62471991e45d4, content=<a href='/topic/show?id=4e9a835154' target=_blank style='color:#2F92EE;'>#GW制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8351, encryptionId=4e9a835154, topicName=GW制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffd5416, createdName=bettycmoon, createdTime=Tue Oct 11 04:04:00 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991300, encodeId=437a1991300f6, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu May 05 06:04:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581567, encodeId=d233158156eaa, content=<a href='/topic/show?id=938b68e713' target=_blank style='color:#2F92EE;'>#Epidiolex#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6877, encryptionId=938b68e713, topicName=Epidiolex)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acc16815920, createdName=ms3415360956839622, createdTime=Wed Mar 23 04:04:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72660, encodeId=9cbce26608f, content=好，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 13:00:00 CST 2016, time=2016-03-22, status=1, ipAttribution=)]
    2016-03-22 1de304d2m86(暂无匿称)

    好，学习了

    0